Tracking Dengvaxia, Qdenga (TAK-003) & Tetravalent Dengue Vaccines
Updated July 2026. Dengue infects hundreds of millions each year across 129 countries, with cases surging due to climate change and urbanization. Three dengue vaccines are now licensed with meaningful global use: Qdenga (TAK-003) by Takeda — now approved in 43+ countries including India (July 2026) and WHO-prequalified since May 2024, with over 32 million doses distributed and no pre-vaccination screening required; Dengvaxia (CYD-TDV) by Sanofi (approved 2015, restricted to seropositive individuals aged 6–45 due to safety concerns — Sanofi has since announced global distribution discontinuation due to low demand); and Butantan-DV, Brazil's Butantan Institute's single-dose live-attenuated tetravalent candidate, approved domestically. All target four dengue serotypes (DENV-1 through DENV-4). The core clinical challenge remains antibody-dependent enhancement (ADE) — where prior infection or incomplete immunity can worsen subsequent infections — which is why serostatus-agnostic vaccines like Qdenga were a major breakthrough. This tracker monitors licensed vaccines, deployment programs, and next-generation candidates including single-dose tetravalent vaccines.
Developer: Sanofi Pasteur
Platform: Live attenuated tetravalent vaccine (chimeric yellow fever-dengue virus)
Efficacy: 60% overall, variable by serotype (42-78%)
Dosing: Three doses at 0, 6, and 12 months
Challenge: Increased risk of severe dengue in seronegative individuals (those never infected). WHO now recommends only for seropositive individuals aged 9-45.
Status: Licensed in 20+ countries but use limited by safety concerns. Pre-vaccination screening recommended.
Developer: Takeda Pharmaceuticals
Platform: Live attenuated tetravalent vaccine (based on DENV-2 backbone)
Efficacy: 80.2% against hospitalized dengue and 73.3% against symptomatic dengue in the pivotal Phase 3 TIDES trial. Seven-year follow-up shows sustained protection — 84.1% reduction in hospitalizations through 4.5 years, and 90.6% after a booster dose.
Dosing: Two subcutaneous doses of 0.5 mL, 3 months apart. Optional booster at 4.5 years extends high-level immunity through ~7 years.
Breakthrough: Safe in both seronegative and seropositive individuals — no increased risk of severe disease in dengue-naive recipients. Approved for individuals aged 4–60 years without pre-vaccination antibody screening.
Status (July 2026): Approved in 43+ countries including EU (Dec 2022), UK (2022), Indonesia (2022), Brazil (2023), Thailand (2023), Argentina (2023), Malaysia (2024), Colombia (2024), Nordic countries, and — as of July 2026 — India (DCGI market authorization). WHO prequalification granted May 9, 2024. More than 32 million doses distributed globally through public and private programs. Post-marketing safety monitoring in Brazil identified rare anaphylaxis (4.4 per 100,000 doses); the package insert has been updated with precautionary measures.
Developer: NIH / Butantan Institute (Brazil)
Platform: Live attenuated tetravalent vaccine
Innovation: Single-dose vaccine showing 90% protection in controlled human infection studies
Status: Phase 3 trial (BRAVE) in Brazil with 16,000 participants. Results expected 2024-2025.
Potential: If successful, could be first single-dose dengue vaccine - major improvement over current 2-3 dose schedules.
Developer: Walter Reed Army Institute / Merck
Platform: Tetravalent purified inactivated vaccine (killed virus)
Advantage: No risk of vaccine virus transmission, may be safer in immunocompromised
Status: Phase 2 trials evaluating safety and immunogenicity
Developer: Merck
Platform: Recombinant subunit vaccine using virus-like particles
Status: Early phase trials, tetravalent formulation in development
Dengue vaccine development is uniquely challenging due to antibody-dependent enhancement (ADE): incomplete immunity can make subsequent infections more severe. Four serotypes (DENV-1 through DENV-4) co-circulate, requiring tetravalent vaccines. Dengvaxia's safety issues in seronegative individuals led to WHO restricting its use. Qdenga represents a breakthrough as the first vaccine safe in all populations. The ideal dengue vaccine would provide: single-dose protection, safety in naive and previously infected individuals, balanced immunity against all 4 serotypes, and long-lasting protection. TV003's single-dose approach and strong CHMI data offer hope for achieving these goals.